RBC Capital Remains a Buy on Arrowhead Pharmaceuticals (ARWR)
In a report released today, Luca Issi from RBC Capital maintained a Buy rating on Arrowhead Pharmaceuticals (ARWR – Research Report), with a ...
Arrowhead Pharmaceuticals (NASDAQ:ARWR) Receives “Buy” Rating from HC Wainwright
HC Wainwright reaffirmed their buy rating on shares of Arrowhead Pharmaceuticals (NASDAQ:ARWR – Free Report) in a research ...
Q3 EPS Forecast for Arrowhead Pharmaceuticals Cut by Analyst
Stock analysts at Leerink Partnrs reduced their Q3 2025 earnings per share estimates for Arrowhead Pharmaceuticals in a ...
Investing3d
Arrowhead Pharmaceuticals director sells shares valued at $20,139
On the other hand, Arrowhead Pharmaceuticals has entered into a significant strategic partnership with Sarepta Therapeutics, involving a $500 million upfront payment and a $325 million equity ...
Arrowhead Pharmaceuticals director sells shares valued at $20,139
The shares were sold at a price of $21 each, totaling $20,139. Following this transaction, Olukotun holds 35,781 shares ...
Strategic Catalysts and Market Potential Drive Buy Rating for Milestone Pharmaceuticals’ CARDAMYST
Analyst Patrick Trucchio from H.C. Wainwright reiterated a Buy rating on Milestone Pharmaceuticals (MIST – Research Report) and keeping the ...
EurekAlert!3d
Study shows promise for treating core symptom of frontotemporal dementia
A new study led by Western researchers found frequent treatment with intranasal oxytocin – a hormone in the brain associated ...
Zacks.com on MSN6d
Guidewire Software (GWRE) Surges 11.5%: Is This an Indication of Further Gains?
Guidewire Software (GWRE) saw its shares surge in the last session with trading volume being higher than average. The latest ...
Morningstar4d
Arrowhead Pharmaceuticals Inc ARWR
We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...